We’re excited to announce the successful closing of our €500 million bond transaction, the latest move to strengthen Grünenthal’s financial foundation and support our ambitious growth plans. This milestone extends our financial flexibility, enabling us to invest further in our strategic priorities, including potential acquisitions and advancing our R&D efforts. With the trust of our investors and the hard work of our team, we are well-positioned to continue delivering innovative pain treatments to more patients and move closer to our vision of a world free of pain. Learn more about our latest bond transaction: https://bit.ly/3VpUHfZ #WeAreGrünenthal #WorldFreeOfPain
Grünenthal Group’s Post
More Relevant Posts
-
🌟A record-breaking 2023 for Grünenthal🌟 Thanks to the commitment of our talented team and partners, I’m pleased to share the fantastic 2023 financial results published by Grünenthal Group this week. Here are some of the highlights: - Our revenue reached a record-breaking €1.8 billion – up 10% compared with 2022. - We maintained a stable adjusted EBITDA of €427 million – allowing us to invest in crucial areas such as mergers & acquisitions, research & development, and seizing growth opportunities in the all-important US market. - Notably, our pipeline continues to flourish – making significant progress in advancing Phase III programmes targeting osteoarthritis-related pain and post-surgical neuropathic pain. These, and many other successes from 2023, would not have been possible were it not for the efforts of every Grünenthal colleague worldwide. In particular, I’d like to recognise those working in my Commercial area for their dedication and contribution to delivering these fantastic results! It’s because of all of you and the impact you make that Grünenthal is able to help improve the lives of millions of patients around the world. #WeAreGrünenthal #WorldFreeOfPain
-
The global M&A landscape is characterised by a dynamic interplay of regulatory changes, digital innovation, and the rising significance of sustainability. At the International Bar Association 21st International Mergers & Acquisitions Conference, Rabindra Jhunjhunwala along with Nicola Charlston, Eric Swedenburg, Dieter Gericke, Arne Grimme, and Jamie Leigh, delved into key trends and challenges in the healthcare and life sciences sector, including the primary drivers of M&A activity, emerging opportunities and risks, evolving regulatory landscapes, and the practical considerations for executing successful healthcare deals. #KhaitanCo
-
-
Concise report with plenty of figures. Have a look, some details may not have been known.
The life sciences sector has been one of the most resilient and innovative industries in the face of the global pandemic and continued economic uncertainty. Our Global Transaction Advisory Group Lifesciences team is pleased to announce the release of our 2024 Health of the Life Sciences Industry Report which analyzes the health of the sector from four perspectives: equity market performance, financial performance, mergers and acquisitions (M&A) activities, and deal sentiments in the board rooms. Discover our key findings: https://okt.to/kiqGuV #AMon #GlobalTransactionAdvisory #LifeSciences #MergersandAcquistions Simon Joyeux, Raheel Khan, Andrew Henoch, Paul Aversano, Anthony Caporrino, Katia Lacy, Stacy Kirshner, Greg Cibuzar, Alison Fink, Jeremy Nanus, Vivian Santora
-
-
Head of Marketing (CMO) - Alliance Management - Ignition // Director at KPMG Switzerland
How have life sciences deals performed over the last few years? Our Life Sciences deals paper summarizes notable European deals and trends of 2023 and provides an outlook for 2024. Explore our paper for more insights. #LifeSciences #Europe #Deals #MergersandAcquisitions #VentureCapital #IPO
-
How have life sciences deals performed over the last few years? Our Life Sciences deals paper summarizes notable European deals and trends of 2023 and provides an outlook for 2024. Explore our paper for more insights. #LifeSciences #Europe #Deals #MergersandAcquisitions #VentureCapital #IPO
Overview and outlook of European Life Sciences deals 2023 & 2024
kpmgswitzerland.smh.re
-
📣 Out now: European Life Sciences deals overview Q3 2024 🔎 We are keeping a close eye on the Life Sciences deal activity in Europe and have gathered all the details and insights from the last quarter. Our report discusses: ● the latest M&A, VC & growth capital, and IPO & follow-on deals ● key year-on-year developments from Q3 2023 to Q3 2024 ● key acquirers and notable investors in the Life Sciences industry 🚀 Ready to stay ahead? Read our full report here: https://lnkd.in/e85MV9X6
-
-
📣 Out now: European Life Sciences deals overview Q3 2024 🔎 We are keeping a close eye on the Life Sciences deal activity in Europe and have gathered all the details and insights from the last quarter. Our report discusses: ● the latest M&A, VC & growth capital, and IPO & follow-on deals ● key year-on-year developments from Q3 2023 to Q3 2024 ● key acquirers and notable investors in the Life Sciences industry 🚀 Ready to stay ahead? Read our full report here: https://lnkd.in/dSznSBUg
-
-
How have life sciences deals performed over the last few years? Our Life Sciences deals paper summarizes notable European deals and trends of 2023 and provides an outlook for 2024. Explore our paper for more insights. #LifeSciences #Europe #Deals #MergersandAcquisitions #VentureCapital #IPO
Overview and outlook of European Life Sciences deals 2023 & 2024
kpmgswitzerland.smh.re
-
How have life sciences deals performed over the last few years? Our Life Sciences deals paper summarizes notable European deals and trends of 2023 and provides an outlook for 2024. Explore our paper for more insights. #LifeSciences #Europe #Deals #MergersandAcquisitions #VentureCapital #IPO
Overview and outlook of European Life Sciences deals 2023 & 2024
kpmgswitzerland.smh.re
-
📣 Out now: European Life Sciences deals overview Q3 2024 🔎 We are keeping a close eye on the Life Sciences deal activity in Europe and have gathered all the details and insights from the last quarter. Our report discusses: ● the latest M&A, VC & growth capital, and IPO & follow-on deals ● key year-on-year developments from Q3 2023 to Q3 2024 ● key acquirers and notable investors in the Life Sciences industry 🚀 Ready to stay ahead? Read our full report here: https://lnkd.in/eM4aGYX2
-
